Physician profile
Herbert E Dempsey
NPI 1245222611
$11,571.30
in general payments reported to CMS, 2019-2025
50 companies · $696 in 2025
The $696 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,704 · 2020: $1,030 · 2021: $2,671 · 2022: $2,087 · 2023: $2,052 · 2024: $1,332 · 2025: $696.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,080.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,079.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,064.36 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $1,603.32 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $1,470.44 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,100.70 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $856.40 | 2019-2025 | |
| Amgen INC. | $519.11 | 2019-2024 | Prolia, Evenity, Repatha |
| Abbott Laboratories | $473.31 | 2021-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $380.39 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Merck Sharp & Dohme LLC | $264.23 | 2019-2023 | Steglatro, Belsomra |
| Novartis Pharmaceuticals Corporation | $247.38 | 2019-2025 | |
| Amarin Pharma, INC. | $226.18 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $219.51 | 2022 | |
| Glaxosmithkline, LLC. | $178.77 | 2019-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Astellas Pharma US INC | $170.58 | 2020-2024 | Veozah, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $162.06 | 2021-2023 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Herbert Dempsey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.